Feasibility of Outpatient Administration of Ciltacabtagene Autoleucel for the Treatment of Relapsed Refractory Multiple Myeloma: The Vanderbilt Experience

Key Points

• Outpatient administration of ciltacabtagene autoleucel shows promise for treating relapsed refractory multiple myeloma, enhancing patient convenience.
• Key evidence indicates successful outpatient procedures with manageable side effects reported in this population.
• Feasibility assessment includes monitoring for treatment outcomes and adverse events associated with cell therapy.
• Highlights the potential for outpatient care to transform treatment protocols for chronic conditions in hematology.